$82.56 -$0.90 (-1.1%)

04:00 PM EST on 11/21/19

Medifast Inc (NYSE:MED)

CAPS Rating: 2 out of 5

The Company is engaged in the production, distribution, and sale of weight management and disease management products and other consumable health and diet products.

Current Price $82.56 Mkt Cap $969.4M
Open $83.31 P/E Ratio 13.23
Prev. Close $83.46 Div. (Yield) $3.00 (3.6%)
Daily Range $81.06 - $83.77 Volume 60,729
52-Wk Range $67.50 - $159.41 Avg. Daily Vol. 453,681

Caps

How do you think NYSE:MED will perform against the market?

Add Stock to CAPS Watchlist

All Players

252 Outperform
53 Underperform
 

All-Star Players

39 Outperform
22 Underperform
 

Wall Street

5 Outperform
2 Underperform
 

Top NYSE:MED Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

poggly57 (< 20)
Submitted March 08, 2011

America is fat and this company will help them get thinner. :) I think this one will be up quite a bit sometime over the next year. Don't know that I'd hold for a long time after that.

sunnyspot (34.95)
Submitted February 04, 2012

Despite brief rally last year after SEC troubles cleared, stock continues to decline, with analysts proposing that clients are moving toward the Weight Watchers style of weight management.

NYSE:MED VS S&P 500 (SPY)

Fools bullish on NYSE:MED are also bullish on:

Fools bearish on NYSE:MED are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about MED.

Recs

0
Member Avatar AnsgarJohn (93.53) Submitted: 6/14/2019 8:41:30 AM : Outperform Start Price: $139.73 NYSE:MED Score: -48.20

Medifast Gross Profitability 204% Sales $568m - $138m COGS / $210m assets = 204%

I’ll start by explaining what the gross profitability anomaly is. It is the ratio of gross profits (revenues less cost of goods sold) to total assets. Rather than relying solely on the income statement, Novy-Marx tied profitability to the balance sheet. Doing so helps to analyze how effectively a company is using its assets to realize gross profits. (A bloated balance sheet will reduce the ratio.) Novy-Marx himself views gross profits as a growth indicator since net earnings can be “punished” for growth-related activities such as advertising and research & development.

Recs

0
Member Avatar gunterle (66.74) Submitted: 12/19/2016 1:24:11 PM : Outperform Start Price: $38.72 NYSE:MED Score: +75.67

signal

Recs

0
Member Avatar rknapton (78.62) Submitted: 8/22/2013 4:27:22 PM : Outperform Start Price: $23.29 NYSE:MED Score: +168.14

Long. Weight loss and weight management food products. Revenue growth seems to be slowing, but perhaps a good value at 16x ttm, 12x fye earnings, along with a very healthy balance sheet.

Leaderboard

Find the members with the highest scoring picks in MED.

Score Leader

mackiealf

mackiealf (77.59) Score: +1,305.28

The Score Leader is the player with the highest score across all their picks in MED.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
mackiealf 77.59 2/17/2009 Outperform NS $4.85 +1,602.16% +296.89% +1,305.28 0 Comment
Lobo0570 92.35 8/10/2007 Outperform 5Y $5.88 +1,303.32% +126.25% +1,177.07 0 Comment
edkeller < 20 9/29/2008 Outperform 1Y $6.20 +1,232.11% +167.16% +1,064.95 1 Comment
MONEYANDPOWER 76.25 7/25/2007 Outperform 1Y $6.48 +1,174.82% +116.89% +1,057.94 0 Comment
ROMERO58 < 20 4/20/2007 Outperform NS $6.64 +1,143.80% +121.35% +1,022.45 0 Comment
callistyler 66.47 2/12/2007 Outperform 3Y $7.14 +1,056.19% +128.84% +927.34 0 Comment
raedward < 20 7/23/2007 Outperform NS $7.30 +1,030.59% +111.88% +918.71 1 Comment
megell 39.15 7/23/2007 Outperform 3W $7.30 +1,030.59% +111.88% +918.71 0 Comment
RagingFoo 30.44 6/21/2007 Outperform 1Y $7.54 +994.25% +116.23% +878.02 1 Comment
smallcapsurfer 84.09 8/22/2008 Outperform 1Y $7.34 +1,025.06% +147.41% +877.65 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for MED.